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Abstract
Background: The measurement of liver volume (LV) is considered to be an effective 
prognosticator for postoperative liver failure in patients undergoing hepatectomy. It is unclear 
whether LV can be used to predict mortality in cirrhotic patients.
Methods: We enrolled 584 consecutive cirrhotic patients who underwent computerized 
topography (CT) of the abdomen for hepatocellular carcinoma surveillance and 50 age, gender, 
race, and BMI-matched controls without liver disease. Total LV (TLV), functional LV (FLV), and 
segmental liver volume (in cm3) were measured from CT imaging. Cirrhotic subjects were 
followed until death, liver transplantation, or study closure date of July 31, 2016. The survival data 
were assessed with log-rank statistics and independent predictors of survival were performed using 
Cox hazards model.
Results: Cirrhotic subjects had significantly lower TLV, FLV, and segmental (all except for 
segments 1, 6, 7) volume when compared to controls. Subjects presenting with hepatic 
encephalopathy had significantly lower TLV and FLV than those without HE (p=0.002). During 
the median follow up of 1,145 days, 112 (19%) subjects were transplanted and 131 (23%) died. 
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TLV and FLV for those who survived were significantly higher than those who were transplanted 
or dead (TLV:1740 vs 1529 vs 1486, FLV 1691 vs 1487 vs 1444,p <0.0001). In the Cox regression 
model, age, MELD score, TLV or FLV were independent predictors of mortality.
Conclusion: Baseline liver volume is an independent predictor of mortality in subjects with 
cirrhosis. Therefore it may be useful to provide these data while performing routine surveillance 
CT scan as an important added value. Further studies are needed to validate these findings and to 
better understand their clinical utility.
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INTRODUCTION
The natural history of cirrhosis is characterized by a compensated stage followed by a 
decompensated stage[1–3]. Transition to a decompensated stage is manifested by the 
development of ascites, hepatic encephalopathy, or bleeding varices secondary to portal 
hypertension[4, 5], The long-term survival of patients in both stages is significantly different 
with compensated patients having a median survival time of more than 10 years compared to 
decompensated patients with overall survival less than 2 years[1–3]. Identification of the 
non-invasive clinical parameters that can accurately predict the clinical progression of liver 
cirrhosis is of importance as it may lead to early intervention to prevent adverse outcomes 
before they develop. The measurement of liver stiffness (LS) using transient elastography is 
commonly used as a method for assessing the degree of fibrosis[6]. The LS-spleen size-to-
platelet ratio is found to be a reliable method predicting variceal bleeding among patients 
with cirrhosis secondary to hepatitis B virus[7]. The ratio can also be used to predict the 
presence of esophageal varices among those with compensated cirrhosis[8]. Patients with 
high LS values (≥18 kPa) have significantly higher risks of developing hepatic 
decompensation compared to those with lower values[9] and LS is useful in screening for 
liver-related and all-cause mortality, as shown in a recent meta-analysis[10]. In addition to 
LS, other non-invasive markers such as enhanced liver fibrosis (ELF) score, aspartate to 
platelet ratio index (APRI), fibrosis-4 (Fib-4) score, as well as MRI imaging derived indices 
such as ADC maps have been explored as the tools to predict liver-related complications in 
patients with cirrhosis[11–16].
Abdominal computer tomography (CT) is commonly performed in patients with suspected 
or known diagnosis of cirrhosis. Several imaging findings suggestive of cirrhosis include an 
irregular or nodular surface, a blunt hepatic edge, parenchymal abnormalities or changes 
compatible with portal hypertension[17, 18]. CT is also used as the screening and diagnostic 
modality for hepatocellular carcinoma (HCC)[19]. CT is associated with increased detection 
of HCC when compared to ultrasound, despite its higher false positive rate[20].
Cirrhosis is characterized histologically by the presence of fibrosis and regenerative nodules. 
Liver volume in cirrhosis subjects varies; however, most are much smaller than normal. 
Imaging-based volumetry has been increasingly utilized in clinical practice to obtain 
accurate measurements of the liver volume [21–24]. This technique is useful in planning for 
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major hepatic resection and living donor liver transplantation where the size of the remnant 
liver and liver graft, respectively, affects surgical outcomes[22]. Liver volume (LV), based 
on MRI imaging was shown to be associated with transplant or death in cirrhotic patients 
independent of MELD scores during a 5-year follow up[23]. However, the other outcomes 
related to the development of portal hypertension were not reported.
Due to advances in computation, rapid semi-automatic complete liver segmentation and 
volumetric analysis may be considered for CT scans of the abdomen in cirrhotic patients.. 
However, until now it was not clear what would be the added value of by providing this 
report. The goals of our study are 1) to compare LV stratified by hepatic segments in a large 
cohort of patients with cirrhosis compared to body-weight matched controls and 2) to 
determine the association between baseline LV and the presence of portal hypertension 
complications, and 3) to determine the prognostic significance of providing routine CT 
derived LV on the long term outcomes of patients with cirrhosis.
METHODS
Study cohort
Subjects were identified retrospectively from consecutive patients with cirrhosis seen in the 
Liver Transplantation clinic at Indiana University Hospital who underwent CT of the 
abdomen for HCC surveillance between January 1-June 30, 2009. The diagnosis of cirrhosis 
was made using radiographic imaging compatible with cirrhosis and/or history of ascites, 
hepatic encephalopathy and/or the presence of esophageal varices on upper gastrointestinal 
endoscopy, or biopsy-proven cirrhosis. All patients were at least 18 years old and had 
baseline laboratory evaluation within 2 weeks from the date of CT evaluation. Patients were 
excluded if they had liver masses such as HCC, metastatic diseases, or hepatic cysts or had 
previous history of hepatic resection. During this period, 584 patients met all the inclusion 
and exclusion criteria. Cirrhosis was determined by Liver biopsy. Baseline demographics, 
clinical characteristics, as well as laboratory values were recorded. Child-Pugh and MELD 
scores were calculated as previously described[25]. Medical records, 
esophagogastroduodenoscopy results, as well as medication lists were reviewed to determine 
whether patients had any complications from portal hypertension such as hepatic 
encephalopathy, ascites, or esophageal varices. Another cohort of 50 controls without 
underlying history of liver diseases who also underwent a CT scan of the abdomen were 
selected. These controls were age, gender, and body mass index (BMI)-matched to those 
with cirrhosis. The study design was approved by the Institutional Review Board at the 
Indiana University Purdue University Indianapolis (IUPUI).
CT scan-based liver volume (LV) measurement
LV measurement from CT imaging was performed using the semi-automated interactive 
software “IntelliSpace Portal Liver Analysis application” (Philips Medical Systems, Best, 
The Netherland). The majority of scans were acquired on a 64 slice Brilliance CT scanner 
(Philips Medical Systems, Best, The Netherland). These were acquired with a slice thickness 
of 4mm ×3 mm, using multi-phase (arterial, portal venous and delayed venous phases) with 
100 to 120 cc of iodinated contrast (Isovue 370). The portal venous phase of the scans was 
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chosen for analysis due to the improved liver density. The software utilized a variational 
approach guided by Hounsfield units and surrounding anatomical structures. The software 
algorithm first identified the liver contour and vessel segmentation. Subsequently, a semi-
automated guided manual placement of 9 key anatomical and vessels landmarks (e.g inferior 
vena cava, middle and right hepatic veins, left and right portal vein bifurcations) was 
performed using the software by each reader, providing the Couinaud hepatic segments[26]; 
in which the volumes were calculated automatically (Supplementary Figure 1). Because the 
liver and intrahepatic vascular volume were calculated simultaneously, the software provided 
2 readouts; total liver volume (liver volume including vascular volume) and functional liver 
volume (liver volume excluding vascular volume). The measurement was performed 
independently by MP and MT. The average time per case was 5 minutes, and the learning 
curve for the software was short[27]. The less experienced reader MP achieved proficiency 
within a short time frame. The inter-observer agreement using Pearson correlation 
coefficient for assessment of the total liver volume and each hepatic segments between both 
MP and MT was 0.97.
Assessment of outcomes and follow up
Only patients with underlying cirrhosis were prospectively followed until death, liver 
transplantation, or study closure date of July 31,2016. Medical records during the follow up 
period were reviewed. For compensated patients without complications of portal 
hypertension (ascites, hepatic encephalopathy, bleeding varices, and HCC) at baseline, the 
development of these complications during the follow up period was recorded.
Statistical analysis
Basic descriptive statistics, including mean, standard deviations (SD), and frequencies 
(percentages) were used to characterize the dataset. Appropriate comparison tests including 
chi-square test, Student’s t-test or analysis of variance (ANOVA) were used. The survival 
data were univariately assessed with Kaplan-Meier survival estimates, and log-rank statistics 
were used for comparison of univariate survival curves. Overall survival was estimated as 
the interval from the date of CT scan imaging to death, transplantation or the end of the 
study on July 31, 2016. Patients were censored at the time of the transplantation. The 
evaluation of independent predictors of survival was conducted using the Cox proportional 
hazards model and reported as hazard ratios (HR) with corresponding 95% confidence 
intervals (95% CI). A P value less than 0.05 was considered statistically significant. All 
analyses were performed with SAS software version 9.4 (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics of patients with cirrhosis and controls
Baseline demographics, clinical characteristics, and laboratory values in patients with 
cirrhosis and controls are shown in Table 1. There were no differences in age, gender-, race, 
and BMI between cases and controls.As expected, patients with cirrhosis had lower levels of 
hemoglobin (12.5 vs. 13.6 g/dl, p=0.002), white blood cells (5.8 vs. 10.3 ×103/mm3, 
p=0.0001), platelet counts (112.8 vs. 276 ×103/mm3, p=0.001), and albumin (3.0 vs. 4.1 
g/dl, p=0.0001), when compared to controls. They had higher levels of AST (77.6 vs. 20.6 
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U/L, p=0.0001), ALT (53.8 vs. 21.4 U/L, p=0.0001), ALP (135.7 vs. 83.4 U/L, p=0.0001), 
and MELD scores (11.2 vs. 4.4, p=0.0001).
Total liver and segmental volumes in patients with cirrhosis and controls
Patients with cirrhosis had significantly lower total liver volume (TLV, 1641 vs. 1786 cm3, 
p=0.02) and functional liver volume (FLV, 1595 vs. 1725 cm3, p=0.04) when compared to 
controls. The results were similar when we adjusted the TLV and FLV with body weight 
(Table 1). We also observed the differences in the hepatic segmental volumes between two 
groups (Table 1). The volume of the caudate lobe (segment 1) was higher in patients with 
cirrhosis than that of controls (44.9 vs. 39.1 cm3), although it did not reach statistical 
significance (p=0.10). Interestingly, patients with cirrhosis had a higher volume of the left 
lobes (segment 2 and segment 3), calculated with and without body weight adjustment,when 
compared to controls (Table 1, p<0.0001). The decrease in total volume in patients with 
cirrhosis was primarily due to the reduction in the volume of the right lobe (segments 4-8, 
1128.7 vs. 1349 cm3, p<0.0001, supplementary Fig 2), notably on segments 4, 5, and 8 
(Table 1). There were no differences in TLV, FLV and segmental volumes among different 
etiologies of cirrhosis (Supplementary Table 1).
Association between liver volumes, baseline MELD score, Child Pugh classification and 
complications of portal hypertension
We next determined the association between the liver volumes and severity of underlying 
liver diseases as indicated by MELD score, Child Pugh classification and the clinical 
presentations of portal hypertension among patients with cirrhosis at baseline. Due to the 
association between LV and body weight (supplementary Fig 3), we used the LV to body 
weight ratio in the analysis. We found an inverse relationship between MELD scores and 
TLV:BW ratio (r=−0.09, p=0.02, Fig 1A) and FLV:BW ratio (r=−0.09,p=0.02, Fig 1B). 
Additionally, TLV:BW ratio and FLV:BW ratio were progressively decreased from patients 
with Child Pugh class A to class C (TLV:BW class A:B:C 21.3:19.5:15.3, p=0.003 and 
FLV:BW class A:B:C 20.7:18.9:14.8,p=0.004, Fig 1C and Table 2). We found that those 
with a history of hepatic encephalopathy (HE) at the time of enrollment had a significantly 
lower TLV:BW (17.9 vs. 20.5,p=0.002) and FLV:BW (17.4 vs. 19.3,p=0.002) compared to 
those without a history of HE (Fig 1D). No differences in TLV:BW and FLV:BW in patients 
with and without complications from portal hypertension secondary to esophageal varices 
(Fig 1E) or ascites (Fig 1F) were observed. Detailed information on LV and segmental 
volume by the presence of HE, esophageal varices, and ascites is shown in Supplementary 
Table 2.
Clinical outcomes of patients with cirrhosis
During a median follow-up period of 3.1 years (1,145 days), 112 (19.3%) cirrhotic patients 
were transplanted and 131 (22.6%) patients died. Clinical characteristics of these patients 
stratified by clinical outcomes are shown in Table 3. Patients who died during the follow up 
were significantly older (58.4±9.6 yrs) than those who were alive (55.9±10.1 yrs) or 
transplanted (53.4±9.9, p=0.0004). They also had higher MELD scores at baseline 
(13.6±8.6). There were several baseline hematological variables which were statistically 
Patel et al. Page 5













differences stratified by clinical outcomes during follow up such as baseline while blood 
cells counts (p=0.03), platelet counts (p=0.0002), and mean corpuscular volume (p=0.003). 
Interestingly, the baseline serum creatinine levels were comparable among 3 groups 
(p=0.39). Patients who died (2.7±0.6 g/dl) or were transplanted (3.0±0.7 g/dl) had lower 
baseline serum albumin compared to those who survived (3.2±0.6 g/dl, p<0.0001).
Total liver and segmental volumes in association with clinical outcomes in patients with 
cirrhosis
Patients who died during the follow up period had significantly lower TLV (1486.6 cm3) and 
FLV (1444.3 cm3) than those who were alive (TLV: 1740.1 cm3; FLV 1691.1 cm3) or 
transplanted (TLV: 1529.6 cm3; FLV 1487.2 cm3; p<0.0001). Similar findings were 
observed when TLV and FLV were normalized by body weight (Table 3).
Factors independently associated with mortality among patients with cirrhosis
On the univariate analysis, older patients (p=0.002), those with higher MELD scores 
(p=0.0001), lower TLV (p=0.001) and lower FLV (p=0.001) had significantly higher risk for 
mortality during the follow up period (Table 4). The effect on TLV and FLV on the mortality 
was primarily driven by the reduction of right hepatic lobe volume (segments 5-8, Table 4) 
In the Cox proportional hazard model after controlling for covariates, age p=0.003), MELD 
score (p=0.001), TLV (model 1, p=0.03, Table 4), and FLV (model 2, p=0.03 Table 4) 
remained independent predictors of mortality in patients with cirrhosis. Using the log-ranked 
analysis to determine the effect of each variable on mortality outcome, we found that 
patients with MELD scores ≥ 11 had significantly higher mortality than those with MELD 
scores < 11 (Fig 2A). The hazard ratio (HR) for those with a MELD score ≥ 11 compared to 
those with a MELD score < 11 on mortality was 1.71 (95% CI 1.18-2.47,p=0.005). For TLV, 
we found that the volume cut-off at 1,635 cm3 was significantly associated with mortality. 
Those with TLV < 1,635 cm3 had significantly higher mortality than those with TLV ≥ 1,635 
cm3 (HR 1.67, 95%CI 1.17-2.43, p=0.005 Fig 2B). For FLV, Those with FLV < 1,589 cm3 
had significantly higher mortality than those with FLV ≥ 1,589 cm3 (HR 1.71, 95%CI 
1.18-2.47, p=0.005 Fig 2C).
DISCUSSION
In our present study, we found that (i) patients with cirrhosis had significantly lower LV 
when compared to age, gender, and BMI-matched controls, (ii) LV was inversely associated 
with MELD score and Child Classification at baseline and associated with the presence of 
HE, and (iii) LV was an independent predictor of mortality in patients with cirrhosis.
Liver volume estimation has been used in pre-operative assessment of patients undergoing 
liver resection or living donor liver transplantation. In the assessment of surgical eligibility, 
key considerations include preoperative baseline liver function, liver volume, and remaining 
liver volume[28]. In fact, the use of CT scan in evaluation of liver volume as part of surgical 
planning has significantly reduced morbidity and mortality after liver surgery[29]. However, 
it has also been noted that due to underlying liver diseases, liver volume and weight may 
differ [21]. In accordance with this observation, it has been hypothesized that liver volume 
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can serve as a non-invasive clinical parameter in predicting long term outcome in patients 
with cirrhosis. In a small study of 25 cirrhotic patients from viral hepatitis, it was found that 
liver volume measured from the CT images was progressively decreased from 1,133 cm3 in 
patients with Child Pugh Class A to 672 cm3 in those with Child Pugh Class C[30]. Patients 
with volume < 750 cm3 who underwent portocaval shunt procedure had significantly 
increased risk of hepatic encephalopathy and death at 1-year follow up[30]. In another study, 
liver volume to ideal body weight ratio trended toward predicting transplant or death in 
patients with cirrhosis, independent of MELD score[23]. Though previous reports provide 
important information on the prognostic significance of liver volume in patients with 
cirrhosis, the studies had a relatively small sample size[30, 31], lack of healthy controls[23], 
and did not report hepatic segmental volume; which may have influenced long term 
outcomes.
Our study consisted of a large cohort of patients with cirrhosis who underwent CT imaging 
as the HCC surveillance protocol. While the liver volume is semi-automatically calculated 
by the software, its measurement requires the manual tracing of the hepatic contours and 
localization of intrahepatic vascular structures and biliary anatomy. Such manual methods 
are operator-dependent; however, we found a high inter-observer agreement between our 
operators. Further, the average liver volume among controls based on the CT imaging in our 
study is comparable to the standard liver volume as measured using the automated 
interactive software to estimate the graft size for living-related liver transplantation[27]; ; 
suggesting the accuracy of the software which was used in our study.
We found that liver volume of patients with cirrhosis was significantly lower than that of 
normal healthy controls. According to Couinaud classification, segment I (caudate lobe) 
receives its supply from both the right and the left portal vein and is drained directly into the 
inferior vena cava by one or more small hepatic veins[32]. Due to a different blood supply 
compared to other hepatic segments, this segment is generally enlarged to compensate for 
the loss of normal liver parenchyma in diseased liver, especially in cirrhosis[33]. While we 
found the higher segment 1 volume in patients with cirrhosis compared to controls, the 
difference was not statistical significant. This may perhaps be explained by the limited 
vector (straight line) segmentation of liver segments compromising segment one analysis. 
We also found comparable liver volume regardless of the etiologies of cirrhosis. As 
previously noted, the measurement of liver volume may not directly reflect hepatic function. 
Child Pugh classification and MELD score are normally used to classify the severity of 
underlying liver disease in patients with cirrhosis[34, 35]. One interesting observation in our 
study is the inverse relationship between liver volume and MELD score and the progressive 
decrease in the liver volume in decompensated stage (Class class B and C) compared to 
those with compensated stage (Child A); suggesting the significant impairment in hepatic 
function with lower liver volume. Our assumption may need to be systematically examined 
in the future studies. Another important finding of our study is the prognostic significance of 
LV in predicting mortality independent of age and MELD score. This is an intriguing 
observation given the relative stability of liver volume[23]. From clinical perspectives, it 
would be of interest to prospectively follow the LV over time and see whether the rate of 
volume reduction can better predict the long term outcomes in this patient and whether the 
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addition of liver volume to the MELD score will improve the accuracy in predicting 
mortality.
The strengths of this study are the large sample size and the inclusion of age, gender, race- 
and BMI-matched controls. We acknowledged the limitations in the retrospective nature of 
our study design and the lack of hepatic function measurement in correlation with our liver 
volume data. In future studies, a prospective study to address these shortcomings and 
compare the prognostic significance between liver volume and another non-invasive 
parameters (such as liver stiffness, APRI, or Fib-4) in predicting long term outcome in 
patients with cirrhosis should be explored.
In conclusion, baseline liver volume is an independent predictor of mortality in patients with 
cirrhosis. Our data suggested that it may be provide an important added value while 
performing routine CT surveillance in patients with cirrhosis. However further studies are 
needed to validate these findings and to better understand their clinical utility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviation list
APRI aspartate to platelet ratio index
CT computer tomography
ELF enhanced liver fibrosis
Fib-4 fibrosis-4
FLV functional liver volume
LS liver stiffness
MELD model for end stage liver disease
TLV total liver volume
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Linear regression analysis between MELD score and total liver volume:body weight ratio 
(A) and functional liver volume:body weight ratio (B). Total liver volume to body weight 
ratio and functional volume to body weight ratio stratified by baseline Child Pugh 
Classification (C), hepatic encephalopathy (D), esophageal varices (E), and ascites (F).
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Kaplan Meier analysis of MELD score (A), total liver volume (TLV, B), and functional liver 
volume (FLV, C) on survival in patients with cirrhosis
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Table 1:







Age (Yrs) 52.3±7.3 55.9±10.1 0.09
Gender (Men, n %) 23 (49%) 360 (61%) 0.08
Race (Whites, n %) 41 (87%) 521 (89%) 0.77
Body weight (Kg) 84.9±18.3 87.1±21.4 0.45
Height (cm) 170.5±12.1 170.8±12.8 0.86
Body mass index (kg/m2) 29.6±6.8 30.1±10.9 0.63
Diagnosis of cirrhosis (n, %)
 - Hepatitis C
 - Alcohol
 - Hepatitis C and alcohol








White blood cell counts (×103/mm3) 10.3±4.5 5.8±371.3 0.0001
Hemoglobin (g/dl) 13.6±1.8 12.5±5.7 0.002
Platelet counts (×103/mm3) 276.4±101.2 112.8±78.4 0.001
Blood urea nitrogen (mg/dl) 13.4±5.8 14.8±12.3 0.13
Creatinine (mg/dl) 0.87±0.19 1.2±1.5 0.0001
Total bilirubin (mg/dl) 1.5±0.8 2.6±3.3 0.91
Alanine aminotransferase (ALT, U/L) 21.4±15.6 53.8±86.1 0.0001
Aspartate aminotransferase (AST, U/L) 20.6±10.9 77.6±107.5 0.0001
Alkaline phosphatase (ALP, U/L) 83.4±30.8 135.7±131.5 0.0001
Albumin (g/dl) 4.1±0.4 3.0±0.7 0.0001
Total protein (g/dl) 7.2±0.6 7.1±3.2 0.30
International normalized ratio (INR) 1.5±0.4 1.7±3.9 0.74
MELD scores 4.4±2.9 11.2±7.2 0.0001
Liver volume without body weight adjustment
Total liver volume (TLV, cm3) 1786.6±421.5 1641.7±555.2 0.02
Functional liver volume (FLV, cm3) 1725.8±414.0 1595.8±540.1 0.04
Portal vein volume (PVV, cm3) 33.0±18.4 29.5±19.6 0.23
Segment 1 volume (cm3) 39.1±20.4 44.9±37.1 0.10
Segment 2 volume (cm3) 210.7±82.2 257.2±185.7 0.001
Segment 3 volume (cm3) 126.7±82.3 182.6±137.3 0.001
Segment 4 volume (cm3) 289.8±103.6 248.4±152.1 0.01
Segment 5 volume (cm3) 293.3±118.1 229.9±139.1 0.0007
Segment 6 volume (cm3) 175.9±91.5 163.7±135.5 0.38
Segment 7 volume (cm3) 275.4±99.4 251.2±124.7 0.11
Segment 8 volume (cm3) 314.8±103.3 232.2±103.9 0.0001



















Liver volume with body weight adjustment
Total volume:body weight (cm3:kg) 21.5±5.8 19.3±6.9 0.01
functional volume:body weight (cm3:kg) 20.8±5.7 18.7±6.7 0.02
Segment 1:BW (cm3/kg) 0.5±0.2 0.5±0.5 0.44
Segment 2:BW (cm3/kg) 2.5±0.9 3.0±1.9 0.01
Segment 3:BW (cm3/kg) 1.5±1.0 2.1±1.6 0.0002
Segment 4:BW (cm3/kg) 3.5±1.5 2.9±1.8 0.0007
Segment 5:BW (cm3/kg) 3.4±1.3 2.7±1.6 0.0001
Segment 6:BW (cm3/kg) 2.1±1.1 1.9±1.5 0.18
Segment 7:BW (cm3/kg) 3.3±1.4 2.9±1.5 0.10
Segment 8:BW (cm3/kg) 3.7±1.2 2.7±1.2 0.0001
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Table 2:
Baseline characteristics, laboratory values, and liver volume measurements stratified by Child Pugh 
Classification.







Age (Yrs) 55.8±10.2 55.0±9.7 55.8±8.6 0.7400
Gender (Men, n %) 72 (59%) 117 (62%) 30 (67%) 0.6600
Race (Whites, n %) 104 (85%) 169 (89%) 41 (91%) 0.2600




Height (cm) 169.5±15.0 171.2±13.9 172.2±9.9 0.4355
Body mass index (kg/m2) 29.0±6.3 31.1±15.9 31.8±8.2 0.2749
White blood cell counts (×103/mm3) 5.7±2.4 5.4±2.9 6.8±3.0 0.0135
Hemoglobin (g/dl) 13.3±2.1 11.8±2.5* 11.8±2.0* <0.0001
Platelet counts (×103/mm3) 136.3±70.9 107.5±69.2* 88.1±44.9*,$ <0.0001
Blood urea nitrogen (mg/dl) 13.9±7.9 14.0±11.0* 19.1±22.6*,$ 0.0305
Creatinine (mg/dl) 1.2±1.6 1.0±1.1 1.5±3.2 0.1585
Total bilirubin (mg/dl) 1.1±0.5 2.4±2.1* 6.2±6.1*,$ <0.0001
Alanine aminotransferase (ALT, U/L) 54.9±54.2 49.7±56.0 45.5±32.4 0.5341
Aspartate aminotransferase (AST, U/L) 60.1±55.7 76.7±64.9* 86.9±47.8*,$ 0.0134
Alkaline phosphatase (ALP, U/L) 105.6±65.0 154.1±164.3* 144.5±65.7* 0.0047
Albumin (g/dl) 3.6±0.6 2.8±0.5* 2.4±0.5*,$ <0.0001
Total protein (g/dl) 7.4±0.7 6.9±0.9* 6.5±1.0* <0.0001
International normalized ratio (INR) 1.2±0.1 1.6±1.5* 5.5±24.3*,$ 0.0161
MELD scores 7.9±5.3 11.3±6.0* 19.2±11.1*,$ <0.0001
Liver volume without body weight adjustment
Total liver volume (TLV, cm3) 1750.8±505.3 1621.4±541.0* 1381.1±503.0*,$ 0.0003
Functional liver volume (FLV, cm3) 1698.4±488.2 1576.7±527.6 1343.3±479.2*,$ 0.0004
Segment 1 volume (cm3) 52.0±51.6 49.0±48.6 49.2±38.9 0.8687
Segment 2 volume (cm3) 284.8±326.8 249.1±112.8 219.3±107.4 0.1521
Segment 3 volume (cm3) 205.3±189.3 179.0±115.6 139.5±97.0*,$ 0.0279
Segment 4 volume (cm3) 279.3±139.8 251.2±125.9 241.1±240.6 0.1880
Segment 5 volume (cm3) 253.3±195.5 223.8±123.3 187.9±88.1 *,$ 0.0330
Segment 6 volume (cm3) 177.8±108.2 158.4±119.5 130.1+106.3*,$ 0.0504
Segment 7 volume (cm3) 257.3±106.3 242.2±128.0 217.6±109.3 0.1518
Segment 8 volume (cm3) 235.3±107.3 227.1±111.1 192.0±84.3*,$ 0.0656
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Liver volume with body weight adjustment
Total volume:body weight (cm3:kg) 21.3±6.5 19.5±10.3* 15.3+6.3*,$ 0.0004
functional volume:body weight (cm3:kg)
20.7±6.1 19.0±10.0* 14.9+6.0*,$ 0.0005
Segment 1:BW (cm3/kg) 0.6±0.7 0.6±0.6 0.5+0.4 0.5290
Segment 2:BW (cm3/kg) 3.4±3.0 3.0±2.0* 2.4±1.1*,$ 0.0456
Segment 3:BW (cm3/kg) 2.5±2.2 2.1±1.9* 1.6+1.1 0.0220
Segment 4:BW (cm3/kg) 3.4±1.8 3.0±2.0 2.7±2.5 0.0671
Segment 5:BW (cm3/kg) 3.1±2.3 2.7±1.8* 2.1±1.1*,$ 0.0132
Segment 6:BW (cm3/kg) 2.1±1.4 1.9±1.5* 1.4±1.1*,$ 0.0102
Segment 7:BW (cm3/kg) 3.2±1.4 2.9±1.9* 2.4±1.4 0.0438
Segment 8:BW (cm3/kg) 2.8±1.3 2.7±1.5 2.1±1.1*,$ 0.0150
*
significant compared to those in Child Class A,
$
significant compared to those in Child Class B













Patel et al. Page 17
Table 3:









Age (Yrs) 55.8±10.1 53.4±9.9* 58.4±9.6* 0.0004
Gender (Men, n %) 206 (61%) 74 (66%) 78 (59%) 0.53
Race (Whites, n %) 301 (89%) 99 (88%) 119 (90%) 0.67
Body weight (Kg) 87.6±20.8 88.4±19.9 85.2±24.2 0.4511
Height (cm) 170.5±13.5 172.5±13.9 170.3±10.2 0.3052
Body mass index (kg/m2) 30.6±12.8 30.1±8.5 29.3±7.4 0.4921
White blood cell counts (×103/mm3) 5.8±3.0 5.2±4.1 6.4±3.4 0.0333
Hemoglobin (g/dl) 12.6±3.0 12.1±2.3 12.7±11.0 0.6081
Platelet counts (×103/mm3) 123.0±86.3 88.7±44.2 107.6±76.0 0.0002
Blood urea nitrogen (mg/dl) 14.1±10.4 14.1±7.5 17.6±18.5 0.0197
Creatinine (mg/dl) 1.2±1.5 1.0±0.9 1.3±2.0 0.3962
Total bilirubin (mg/dl) 2.2±2.9 2.6±2.0* 3.7±4.7*,$ <0.0001
Alanine aminotransferase (ALT, U/L) 55.6±104.9 53.9±63.4 48.7±35.7 0.7485
Aspartate aminotransferase (AST, U/L) 76.4±131.9 78.8±71.9 79.1±49.4 0.9608
Alkaline phosphatase (ALP, U/L) 131.1±138.7 142.6±92.3 139.1±140.9 0.6780
Albumin (g/dl) 3.2±0.6 3.0±0.7* 2.8±0.6*,$ <0.0001
Total protein (g/dl) 7.2±4.1 6.9±0.9 6.9±1.0 0.5521
International normalized ratio (INR) 1.4±1.0 3.0±15.5 1.6±0.5 0.1272
MELD scores 10.0±6.3 12.0±7.2* 13.6±8.6*,$ <0.0001
Liver volume without body weight adjustment
Total liver volume (TLV, cm3) 1740.1±574.4 1529.7±506.8* 1486.6±495.6*,$ <0.0001
Functional liver volume (FLV, cm3) 1691.7±558.0 1487.2±488.8* 1444.3±487.5*,$ <0.0001
Segment 1 volume (cm3) 44.8±48.0 41.6±42.4 48.5±49.2 0.5375
Segment 2 volume (cm3) 256.8±147.8 277.9±334.9 242.8±137.0 0.3392
Segment 3 volume (cm3) 198.5±152.7 161.5±104.4* 161.7±114.6* 0.0062
Segment 4 volume (cm3) 259.2±147.8 234.6±126.0 228.8±177.3 0.0911
Segment 5 volume (cm3) 249.1±154.8 206.2±117.5* 200.7±102.7*,$ 0.0005
Segment 6 volume (cm3) 175.7±145.8 147.4±97.1 149.0±135.0 0.0563
Segment 7 volume (cm3) 269.2±154.9 226.7±104.1* 226.5±106.9* 0.0003
Segment 8 volume (cm3) 247.0±105.5 216.0±100.7* 207.6±97.4*,$ 0.0002
Liver volume with body weight adjustment
Total volume:body weight (cm3:kg) 20.6±8.9 17.9±7.4* 18.4±7.0*,$ 0.0016





















functional volume:body weight (cm3:kg) 20.0±8.7 17.4±7.1* 17.8±6.8* 0.0016
Segment 1:BW (cm3/kg) 0.5±0.6 0.5±0.5 0.6±0.7 0.1459
Segment 2:BW (cm3/kg) 3.1±1.8 3.2±3.0 3.0±1.9 0.8138
Segment 3:BW (cm3/kg) 2.4±2.1 1.9±1.3* 2.0±1.4*,$ 0.0092
Segment 4:BW (cm3/kg) 3.1±2.1 2.7±1.7 2.8±2.0 0.1347
Segment 5:BW (cm3/kg) 2.9±1.9 2.4±1.5 2.4±1.2 0.0034
Segment 6:BW (cm3/kg) 2.0±1.5 1.7±1.3 1.9±1.9 0.2052
Segment 7:BW (cm3/kg) 3.2±1.7 2.7±1.4* 2.8±1.4* 0.0050
Segment 8:BW (cm3/kg) 2.9±1.3 2.5±1.3* 2.5±1.2* 0.0028
*
significant compared to those who were alive,
$
significant compared to those who were transplanted
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Table 4:
Univariate and multivariate Cox regression analysis on the predictors of mortality in patients with cirrhosis













Age (Yrs) 1.03 (1.01-1.05) 0.002 1.03 (1.01-1.05) 0.003 1.03 (1.01-1.05) 0.003
Gender (M vs. F) 0.89 (0.61-1.30) 0.55 - - - -
Race (Whites vs. African American) 0.88 (0.63-2.31) 0.88 - - - -
Body mass index (kg/m2) 0.96 (0.98-1.02) 0.96 - - - -
MELD score 1.041 (1.025-1.057) 0.0001 1.04 (1.02-1.06) 0.0001 1.04 (1.02-1.06) 0.0001
Total liver volume (TLV, cm3) 0.98 (0.98-0.99) 0.001 0.99 (0.99-1.00) 0.03 - -
Functional liver volume (FLV, cm3) 0.98 (0.98-0.99) 0.001 - - 0.99 (0.99-1.00) 0.03
Segment 1 volume (cm3) 1.002 (0.99-1.005) 0.31 - - - -
Segment 2 volume (cm3) 0.99 (0.99-1.001) 0.19 - - - -
Segment 3 volume (cm3) 0.99 (0.99-1.00) 0.08 - - - -
Segment 4 volume (cm3) 0.99 (0.99-1.00) 0.10 - - - -
Segment 5 volume (cm3)
^ 0.98 (0.96-0.99) 0.01 - - - -
Segment 6 volume (cm3)
^ 0.99 (0.96-0.99) 0.04 - - - -
Segment 7 volume (cm3)
^ 0.99 (0.96-0.99) 0.04 - - - -
Segment 8 volume (cm3)
^ 0.99 (0.96-0.99) 0.03 - - - -
*
model 1 adjusted for age, MELD, and total liver volume (TLV), model 2 adjusted for age, MELD, and functional liver volume (FLV).
^
only segment 5 independently associated with mortality adjusted for age and MELD (HRs 0.99, p=0.05)
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